[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
13-Dec-2013

[ | E-mail ] Share Share

Contact: John Ascenzi
ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia

National award honors CHOP scientist for career work in gene therapy for hemophilia

Dr. Katherine High receives E. Donnall Thomas Prize from American Society of Hematology

IMAGE: Dr. Katherine High delivered the 2013 E. Donnall Thomas Lecture to the American Society of Hematology.

Click here for more information.

Katherine A. High, M.D., of The Children's Hospital of Philadelphia (CHOP) was honored for her trailblazing scientific and clinical research in the bleeding disorder hemophilia when she received the 2013 E. Donnall Thomas Prize from the American Society of Hematology (ASH) at its annual meeting on Dec. 9 in New Orleans.

Named for the late Nobel Prize laureate E. Donnall Thomas, the award recognizes pioneering research achievements in hematology that have helped move the field forward. An internationally recognized expert in the molecular basis of hemophilia, Dr. High has developed novel approaches to correcting hemophilia with gene therapy in studies over the past two decades. Her studies continue today in a current NIH-funded clinical trial for hemophilia.

The Prize recipient customarily delivers the E. Donnall Thomas Lecture to the ASH conference audience. Dr. High's lecture, "Sailing to Ithaca: Gene Therapy's Odyssey from Investigational Agent to Therapeutic Product," described the successes and obstacles of the evolving science and practice of gene therapy as it pursues the goal of offering long-lasting treatments of previously incurable diseases.

In presenting the E. Donnall Thomas Prize, ASH president Janis L. Abkowitz, M.D., said, "Dr. High is unquestionably a leader in gene therapy and has made remarkable, groundbreaking contributions to the field, demonstrating creativity, determination, and the ability to overcome numerous obstacles. Through her countless discoveries, Dr. High has transformed the notion of utilizing genetically engineered mechanisms for treatment of incurable inherited disorders from a distant vision to reality."

Dr. High is the founder and director of the Center for Cellular and Molecular Therapeutics at The Children's Hospital of Philadelphia. She also is a Howard Hughes Medical Institute Investigator, the William H. Bennett Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania, and an attending physician at CHOP. A former president of the American Society of Gene and Cell Therapy, she also is an elected member of both the Institute of Medicine and the American Academy of Arts and Sciences. She is a scientific co-founder and advisor to Spark Therapeutics, a fully integrated gene therapy company launched in October 2013 with a capital investment from CHOP.

###

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program receives the highest amount of National Institutes of Health funding among all U.S. children's hospitals. In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.